Fujian Cosunter Pharmaceutical Co Ltd (300436) - Net Assets
Based on the latest financial reports, Fujian Cosunter Pharmaceutical Co Ltd (300436) has net assets worth CN¥468.48 Million CNY (≈ $68.55 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.52 Billion ≈ $222.40 Million USD) and total liabilities (CN¥1.05 Billion ≈ $153.85 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Fujian Cosunter Pharmaceutical Co Ltd (300436) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥468.48 Million |
| % of Total Assets | 30.82% |
| Annual Growth Rate | 14.87% |
| 5-Year Change | -31.82% |
| 10-Year Change | -23.58% |
| Growth Volatility | 67.07 |
Fujian Cosunter Pharmaceutical Co Ltd - Net Assets Trend (2011–2024)
This chart illustrates how Fujian Cosunter Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Fujian Cosunter Pharmaceutical Co Ltd total assets for the complete picture of this company's asset base.
Annual Net Assets for Fujian Cosunter Pharmaceutical Co Ltd (2011–2024)
The table below shows the annual net assets of Fujian Cosunter Pharmaceutical Co Ltd from 2011 to 2024. For live valuation and market cap data, see 300436 company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥396.78 Million ≈ $58.06 Million |
-30.30% |
| 2023-12-31 | CN¥569.24 Million ≈ $83.30 Million |
-40.43% |
| 2022-12-31 | CN¥955.62 Million ≈ $139.84 Million |
-8.97% |
| 2021-12-31 | CN¥1.05 Billion ≈ $153.63 Million |
+80.39% |
| 2020-12-31 | CN¥581.99 Million ≈ $85.16 Million |
+1.44% |
| 2019-12-31 | CN¥573.74 Million ≈ $83.96 Million |
+2.03% |
| 2018-12-31 | CN¥562.35 Million ≈ $82.29 Million |
+1.87% |
| 2017-12-31 | CN¥552.05 Million ≈ $80.78 Million |
-0.06% |
| 2016-12-31 | CN¥552.36 Million ≈ $80.83 Million |
+6.39% |
| 2015-12-31 | CN¥519.20 Million ≈ $75.97 Million |
+230.97% |
| 2014-12-31 | CN¥156.87 Million ≈ $22.96 Million |
+9.62% |
| 2013-12-31 | CN¥143.10 Million ≈ $20.94 Million |
+31.78% |
| 2012-12-31 | CN¥108.59 Million ≈ $15.89 Million |
+65.95% |
| 2011-12-31 | CN¥65.43 Million ≈ $9.58 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Fujian Cosunter Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2487.7% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CN¥159.27 Million | 44.22% |
| Other Components | CN¥652.32 Million | 181.11% |
| Total Equity | CN¥360.18 Million | 100.00% |
Fujian Cosunter Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Fujian Cosunter Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Madison Square Garden Entertainment Corp
NYSE:MSGE
|
$2.73 Billion |
|
Emerald Resources NL
AU:EMR
|
$2.73 Billion |
|
Remitly Global Inc
NASDAQ:RELY
|
$2.73 Billion |
|
Union Bank of Taiwan
TW:2838
|
$2.74 Billion |
|
Hesai Group Sponsored ADR
NASDAQ:HSAI
|
$2.73 Billion |
|
Shanghai Tunnel Engineering Co Ltd
SHG:600820
|
$2.73 Billion |
|
TISCO Financial Group Public Company Limited
BK:TISCO
|
$2.73 Billion |
|
Beijing Highlander Digital Technology Co Ltd
SHE:300065
|
$2.73 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Fujian Cosunter Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 516,483,180 to 360,178,823, a change of -156,304,357 (-30.3%).
- Net loss of 156,304,351 reduced equity.
- Dividend payments of 17,418,291 reduced retained earnings.
- Other factors increased equity by 17,418,285.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-156.30 Million | -43.4% |
| Dividends Paid | CN¥17.42 Million | -4.84% |
| Other Changes | CN¥17.42 Million | +4.84% |
| Total Change | CN¥- | -30.26% |
Book Value vs Market Value Analysis
This analysis compares Fujian Cosunter Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 51.87x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 192.49x to 51.87x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥0.61 | CN¥117.30 | x |
| 2012-12-31 | CN¥0.97 | CN¥117.30 | x |
| 2013-12-31 | CN¥1.27 | CN¥117.30 | x |
| 2014-12-31 | CN¥1.25 | CN¥117.30 | x |
| 2015-12-31 | CN¥4.64 | CN¥117.30 | x |
| 2016-12-31 | CN¥3.91 | CN¥117.30 | x |
| 2017-12-31 | CN¥3.95 | CN¥117.30 | x |
| 2018-12-31 | CN¥4.03 | CN¥117.30 | x |
| 2019-12-31 | CN¥4.03 | CN¥117.30 | x |
| 2020-12-31 | CN¥4.11 | CN¥117.30 | x |
| 2021-12-31 | CN¥6.98 | CN¥117.30 | x |
| 2022-12-31 | CN¥5.83 | CN¥117.30 | x |
| 2023-12-31 | CN¥3.24 | CN¥117.30 | x |
| 2024-12-31 | CN¥2.26 | CN¥117.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Fujian Cosunter Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -43.40%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -35.41%
- • Asset Turnover: 0.31x
- • Equity Multiplier: 3.99x
- Recent ROE (-43.40%) is below the historical average (7.31%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 51.69% | 32.20% | 0.96x | 1.67x | CN¥27.28 Million |
| 2012 | 39.74% | 34.78% | 0.83x | 1.38x | CN¥32.30 Million |
| 2013 | 40.01% | 32.14% | 0.90x | 1.38x | CN¥42.95 Million |
| 2014 | 53.40% | 32.92% | 1.14x | 1.43x | CN¥68.08 Million |
| 2015 | 19.93% | 33.50% | 0.51x | 1.16x | CN¥51.57 Million |
| 2016 | 12.02% | 21.23% | 0.45x | 1.27x | CN¥11.18 Million |
| 2017 | 6.08% | 11.33% | 0.40x | 1.33x | CN¥-21.64 Million |
| 2018 | 2.98% | 4.10% | 0.47x | 1.54x | CN¥-38.92 Million |
| 2019 | 1.91% | 2.59% | 0.46x | 1.59x | CN¥-45.62 Million |
| 2020 | 2.57% | 4.02% | 0.37x | 1.74x | CN¥-42.84 Million |
| 2021 | -3.34% | -9.42% | 0.26x | 1.39x | CN¥-139.22 Million |
| 2022 | -13.72% | -33.03% | 0.26x | 1.61x | CN¥-220.25 Million |
| 2023 | -67.49% | -82.46% | 0.26x | 3.13x | CN¥-400.24 Million |
| 2024 | -43.40% | -35.41% | 0.31x | 3.99x | CN¥-192.32 Million |
Industry Comparison
This section compares Fujian Cosunter Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,176,632,363
- Average return on equity (ROE) among peers: 2.79%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Fujian Cosunter Pharmaceutical Co Ltd (300436) | CN¥468.48 Million | 51.69% | 2.24x | $2.73 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $1.06 Billion | 5.59% | 4.55x | $1.22 Billion |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $560.87 Million | 4.60% | 0.22x | $438.59 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $9.78 Billion | 0.44% | 0.12x | $5.18 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $14.31 Billion | 12.41% | 0.56x | $2.81 Billion |
| Wedge Industrial Co Ltd (000534) | $1.10 Billion | 8.67% | 0.93x | $2.95 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $184.00 Million | 12.94% | 0.09x | $13.85 Billion |
| Hainan Haiyao Co Ltd (000566) | $294.63 Million | -32.00% | 2.31x | $949.23 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $583.33 Million | 3.29% | 0.50x | $391.07 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $2.55 Billion | 4.67% | 3.16x | $1.03 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.35 Billion | 7.34% | 0.44x | $3.30 Billion |
About Fujian Cosunter Pharmaceutical Co Ltd
Fujian Cosunter Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. It offers drugs for anti-HBV, liver diseases, hepatobiliary disease drugs, metabolism and digestive system, respiratory, cardiovascular, men's health, and other fields. Fujian Cosunter Pharmaceutical Co., Ltd. was founded in 2001 and is headquartered in Fuzh… Read more